- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 08.08. | CHOSA ONCOLOGY AB: CHOSA's presents data on the carboplatin response predictor in breast cancer patients on the annual ESMO conference | 2 | Cision News | ||
| 01.08. | Spotlight Stock Market: Market Notice 145/25 - Information regarding CHOSA Oncology AB's subscription option | 2 | Cision News | ||
| CHOSA ONCOLOGY Aktie jetzt für 0€ handeln | |||||
| 01.08. | CHOSA ONCOLOGY AB: Chosa Oncology's warrants of series TO 2 to be admitted to trading | 1 | Cision News | ||
| 01.08. | Spotlight Stock Market: Market Notice 144/25 - Last day of trading in CHOSA Oncology AB's BTU | 2 | Cision News | ||
| 31.07. | CHOSA ONCOLOGY AB: Chosa Oncology announces the last day of trading in BTU | 1 | Cision News | ||
| 31.07. | Spotlight Stock Market: Market Notice 143/25 - Trading halt in CHOSA Oncology AB's BTU | 1 | Cision News | ||
| 01.07. | CHOSA ONCOLOGY AB: CHOSA extends the timeline for biopsy collection prior to publication from the SPLENDOUR study | 1 | Cision News | ||
| 27.06. | CHOSA ONCOLOGY AB: Chosa Oncology announces outcome in rights issue | 2 | Cision News | ||
| 25.06. | CHOSA ONCOLOGY AB: Last subscription day in Chosa's subscription period | 2 | Cision News | ||
| 25.06. | CHOSA ONCOLOGY AB: CHOSA files new patent application to predict which patients may benefit from platinum chemotherapy and immunotherapy | 5 | Cision News | ||
| 13.06. | Bulletin from the annual general meeting on 13 June 2025 in Chosa Oncology AB | 1 | Cision News | ||
| 12.06. | The subscription period in Chosa Oncology AB's rights issue begins today - the company invites to a webcast presentation | 2 | Cision News | ||
| 10.06. | Chosa Oncology AB publishes information document in connection with rights issue of units | 2 | Cision News | ||
| 09.06. | CHOSA ONCOLOGY AB: CHOSA Oncology invites investors to two upcoming presentations | 1 | Cision News | ||
| 06.06. | XFRA CAPITAL ADJUSTMENT INFORMATION - 06.06.2025 | 307 | Xetra Newsboard | Das Instrument 37P FR0010341032 FONCIERE INEA SA EO 14,39 EQUITY wird cum Kapitalmassnahme gehandelt am 06.06.2025 und ex Kapitalmassnahme am 09.06.2025 The instrument 37P FR0010341032 FONCIERE INEA... ► Artikel lesen | |
| 03.06. | Spotlight Stock Market: Market Notice 101/25 - Information regarding the rights issue from CHOSA Oncology AB | 3 | Cision News | ||
| 02.06. | Chosa Oncology AB resolves on a directed issue of units and on a rights issue of units to provide funds for reaching several value-enhancing milestones | 3 | Cision News | ||
| 23.05. | CHOSA ONCOLOGY AB: CHOSA submits ESMO abstract on carboplatin response in breast cancer patients | 2 | Cision News | ||
| 13.05. | Notice of annual general meeting in Chosa Oncology AB | 2 | Cision News | ||
| 09.05. | CHOSA ONCOLOGY AB: CHOSA- Extending CHOSA's Platin DRP: Predicting Carboplatin Efficacy in Breast Cancer | 2 | Cision News |
1 2 Weiter >>
21 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| DYNE THERAPEUTICS | 12,380 | 0,00 % | Dyne Therapeutics, Inc.: Dyne Therapeutics Announces FDA Breakthrough Therapy Designation for DYNE-251 in Duchenne Muscular Dystrophy (DMD) | - Data from the DELIVER registrational expansion cohort is expected in late 2025, with a potential BLA submission for U.S. accelerated approval anticipated in early 2026 - WALTHAM, Mass., Aug.... ► Artikel lesen | |
| AVIDITY BIOSCIENCES | 46,550 | 0,00 % | Avidity Biosciences, Inc.: Avidity Biosciences Reports Second Quarter 2025 Financial Results and Recent Highlights | Aligned with FDA on del-brax accelerated and full approval pathways for FSHD, reported positive topline data from Phase 1/2 FORTITUDE trial, and initiated global... ► Artikel lesen | |
| BOLT PROJECTS | 8,910 | 0,00 % | Pre-market Movers: Sonoma Pharmaceuticals, Bolt Projects, Ibotta, TeraWulf, 180 Life Sciences | BRASILIA (dpa-AFX) - The following are some of the stocks making big moves in Thursday's pre-market trading (as of 08.50 A.M. ET).In the Green Sonoma Pharmaceuticals, Inc. (SNOA) is up over... ► Artikel lesen | |
| ITEOS THERAPEUTICS | 10,105 | 0,00 % | iTeos Therapeutics Inc.: iTeos Therapeutics Enters into Agreement to Be Acquired by Concentra Biosciences for $10.047 in Cash per Share Plus a Contingent Value Right | WATERTOWN, Mass. and GOSSELIES, Belgium, July 21, 2025 (GLOBE NEWSWIRE) -- iTeos Therapeutics, Inc. ("iTeos") (Nasdaq: ITOS) today announced that it has entered into a definitive merger agreement... ► Artikel lesen | |
| VALNEVA | 5,080 | +6,59 % | Valneva: Operativer Cashburn deutlich verringert - Umsatz steigt | Valneva hat im ersten Halbjahr 2025 die Gesamterlöse um 37,8 Prozent auf 97,6 Millionen Euro gesteigert. Der Umsatz aus Produktverkäufen stieg um 33,3 Prozent auf 91 Millionen Euro. Das Unternehmen... ► Artikel lesen | |
| RECURSION PHARMACEUTICALS | 5,765 | 0,00 % | Recursion Pharmaceuticals (RXRX) Expands AI Drug Discovery Pipeline with New Clinical Candid | ||
| ARS PHARMACEUTICALS | 14,540 | +0,48 % | ARS Pharmaceuticals stock maintains Strong Buy rating at Raymond James on strong neffy sales | ||
| IMMUNOME | 10,280 | 0,00 % | Immunome Inc. - 10-Q, Quarterly Report | ||
| LENZ THERAPEUTICS | 37,870 | 0,00 % | LENZ Therapeutics, Inc.: LENZ Therapeutics and Lotus Pharmaceutical Announce Exclusive License and Commercialization Agreement for LNZ100 in the Republic of Korea and Southeast Asia | SAN DIEGO and TAIPEI, Taiwan, May 09, 2025 (GLOBE NEWSWIRE) -- LENZ Therapeutics, Inc. (Nasdaq: LENZ) and Lotus Pharmaceutical Co., Ltd. ("Lotus", TWSW Stock Code: 1795) today announced an exclusive... ► Artikel lesen | |
| EVOTEC | 6,264 | -1,45 % | Evotec-Aktie: Kurs heute im Minus (6,566 €) | Die Evotec-Aktie notiert heute etwas leichter. Das Papier kostete zuletzt 6,57 Euro. Heute hat sich an der deutschen Börse die Aktie von Evotec zwischenzeitlich um 3,13 Prozent verbilligt. Der Kurs... ► Artikel lesen | |
| SUMMIT THERAPEUTICS | 26,690 | 0,00 % | Summit Therapeutics: Ivonescimab Data from Global Phase III HARMONi Study to be Showcased at Presidential Symposium at WCLC 2025 | Ivonescimab to be Featured at WCLC Presidential Symposium for Second Consecutive Year
Summit Therapeutics Inc. (NASDAQ: SMMT) ("Summit," "we," or the "Company") today announced that data from the... ► Artikel lesen | |
| VIR BIOTECHNOLOGY | 4,520 | 0,00 % | Vir Biotechnology, Inc.: Vir Biotechnology Announces Preliminary 24-Week Post-End of Treatment Data for Tobevibart and Elebsiran Combinations in Chronic Hepatitis B From the MARCH Study | HBsAg loss 24 weeks post-end of treatment achieved in 17% and 21% of participants with low baseline HBsAg receiving tobevibart elebsiran without or with PEG-IFNa, respectively As previously... ► Artikel lesen | |
| FULCRUM THERAPEUTICS | 6,820 | 0,00 % | Fulcrum Therapeutics, Inc.: Fulcrum Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | CAMBRIDGE, Mass., Aug. 08, 2025 (GLOBE NEWSWIRE) -- Fulcrum Therapeutics, Inc.® (Nasdaq: FULC), a clinical-stage biopharmaceutical company focused on developing small molecules to improve the lives... ► Artikel lesen | |
| ARCELLX | 74,01 | 0,00 % | Arcellx, Inc.: Arcellx Announces Its Participation at TD Cowen's 6th Annual Oncology Innovation Summit and Its Investor Event During EHA2025 | Arcellx, Inc. (NASDAQ: ACLX), a biotechnology company reimagining cell therapy through the development of innovative immunotherapies for patients with cancer and other incurable diseases, today announced... ► Artikel lesen | |
| ADMA BIOLOGICS | 16,990 | 0,00 % | ADMA Biologics, Inc.: ADMA Biologics Announces Second Quarter 2025 Financial Results and Provides Business Update | 2Q 2025 Total Revenue of $122.0 Million, a 14% YoY Increase, and a 29% YoY Increase Excluding a Prior Year Non-Recurring Item 2Q 2025 GAAP Net Income of $34.2 Million, a 7% YoY Increase 2Q 2025 Adjusted... ► Artikel lesen |
Das Unternehmen CHOSA ONCOLOGY AB kann der Branche Biotechnologie zugeordnet werden. Mit einer aktuellen Kursveränderung von +0,009 (+17,82 %) liegt der Kurs bei 0,060 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu CHOSA ONCOLOGY AB finden Sie auf Wallstreet Online.